Trevi Therapeutics, Inc. $TRVI Shares Bought by BIT Capital GmbH

BIT Capital GmbH grew its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 1,829.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 130,000 shares of the company’s stock after purchasing an additional 123,261 shares during the quarter. BIT Capital GmbH’s holdings in Trevi Therapeutics were worth $1,628,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of TRVI. Goldman Sachs Group Inc. lifted its stake in shares of Trevi Therapeutics by 34.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,056,891 shares of the company’s stock worth $13,232,000 after acquiring an additional 269,437 shares in the last quarter. AXQ Capital LP raised its stake in Trevi Therapeutics by 43.0% during the fourth quarter. AXQ Capital LP now owns 22,204 shares of the company’s stock valued at $278,000 after buying an additional 6,680 shares in the last quarter. Intech Investment Management LLC raised its stake in Trevi Therapeutics by 14.8% during the fourth quarter. Intech Investment Management LLC now owns 29,070 shares of the company’s stock valued at $364,000 after buying an additional 3,741 shares in the last quarter. Kingsview Wealth Management LLC acquired a new stake in Trevi Therapeutics during the fourth quarter valued at approximately $133,000. Finally, Geode Capital Management LLC raised its stake in Trevi Therapeutics by 8.6% during the fourth quarter. Geode Capital Management LLC now owns 2,412,885 shares of the company’s stock valued at $30,214,000 after buying an additional 191,959 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI opened at $13.33 on Friday. The stock has a fifty day moving average price of $13.76 and a two-hundred day moving average price of $12.40. The firm has a market cap of $1.89 billion, a P/E ratio of -41.66 and a beta of 1.04. Trevi Therapeutics, Inc. has a 1 year low of $5.41 and a 1 year high of $16.12.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). On average, research analysts predict that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on TRVI shares. Morgan Stanley restated an “overweight” rating and set a $20.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Stifel Nicolaus set a $30.00 price objective on Trevi Therapeutics in a research note on Friday, May 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Trevi Therapeutics currently has an average rating of “Buy” and a consensus target price of $22.90.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.